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The development of bacterial resistance to antirnicrobials
is a matter of great importance; if sensitive organisms are
supplanted by resistant ones, then a previously potent drug
may become useless. Over the last 3 decades there has
been a continuing race between the discovery of new anti-
biotics and the growing resistance of microorganisms to
existing antimicrobial agents.
The development of resistance of bacteria during
therapy is essentially due to a remarkable, and at times
elaborate, capacity of these microbes to circumvent the
action of the antibiotics, rather than to any clearly defined
in vivo changes involving susceptibility of the host.
Furthermore, this enlarging frontier of resistance of patho-
gens to antimicrobials has its origins in, and is largely
explained by, a study of microbial genetics. Drug resist-
ance is due to mutation and is therefore entirely pre-
adaptive. Moreover, such drug-resistant organisms may be
either drug tolerant, when there exist physiologic path-
ways unaffected by the antibiotic, or drug destroying (e.g.
penicillinase-producing staphylococci). The drug acts as a
selecting agent, destroying or suppressing the sensitive
forms, and the resistant forms then proliferate. This pro-
cess may occur in 3 main ways:
(a) Drug resistance may arise in a single clone or strain
of organism.
(b) The original sensitive organism and the resistant
replacing organism are different strains of the same species.
(c) The original drug-sensitive population is replaced by
a different species, which is drug resistant.
The origin and incidence of resistance of microbes is
in a large measure due to the prevalence of the drug in
their environment (e.g. widespread use and misuse of anti-
biotics) but is also due to selection by natural exposure to
the antibiotic-producing fungi in the ground or by selec-
tive pressures bearing only a fortuitous relation to anti-
biotics.'
Not only is this problem of antibiotic resistance of great
heuristic and clinical importance, but the field itself has
grown and mushroomed in a startling fashion during the
last 10 years. A complete review of the entire subject is
impracticable in an article of this nature. Our attention,
therefore, will be focused primarily on 3 major aspects:
the nature and mechanism of evolution of drug resistance,
the extent and changing pattern of this resistance, and a
brief glimpse at possible therapeutic measures.
THE NATURE AND INHERITANCE OF RESISTANCE TO
ANTIBIOTICS
In the past 20 years, bacteria have become one of the
groups of organisms most intensively studied genetically
and biochemically. Cytologic and genetic studies hav~
demonstrated that the genetic material of bacterial cells
consists of single molecules of deoxyribonucleic acid
(DNA). The genetic material of all other free-living
organisms is also DNA, but the bacteria and blue-green
'Date received: 1 March 1968.
algae differ from higher plants and animals in that the
nucleus consists of only a single DNA molecule without
the nuclear proteins characteristic of the chromosomes of
higher organisms and is not separated from the cytoplasm
by a nuclear membrane. Bacterial cells on the whole lack
internal membranes and membrane-bound organelles, and
most of the chemical reactions such as respiration and
photosynthesis, which are confined to these organelles in
higher organisms, take place on the inner surface of the
cell membrane in bacteria. The differences in membranes,
together with other differences such as the lack of the
usual type of mitotic apparatus in bacteria, have prompted
cytologists to class these types of cells as 'prokaryotes', as
distinct from 'eukaryotes' which include all higher plants
and animals.'
The usefulness of antibiotics in treating disease resides
in their differential action on the cells of bacteria and
those of the host organism, which in turn depends on the
differences in metabolism and structure between the two
types of cells. For example, one large group of antibiotics
affects the bacterial cell membrane (e.g. the bacteriocidal
drugs such as the penicillins, cephalosporins, bacitracin,
ristocetin, the polymixins, and perhaps the aminoglyco-
sides, streptomycin, kanamycin and neomycin).
The genes of prokaryotes appear to function in a
manner similar to those of eukaryotes, that is, in control-
ling the cellular production of proteins by specifying the
synthesis of messenger, transfer and ribosomal RNA mole-
cules. However, minor differences must occur, as another
large group of antibiotics, which may be classified as
bacteriostatic or cytostatic, work by interfering with some
step in the chain of events leading from the gene to the
synthesis of the completed protein. Some (e.g. cWoramphe-
nicol, echinomycin, daunomycin, nogalamycin, mithra-
mycin, actinomycin, mitomycin and puromycin)3.' interfere
with the duplication of DNA, the transcription of DNA
into RNA or the stability or correct functioning of RNA
molecules. Others, such as streptomycin and the bacterio-
statics, chloramphenicol, oleandomycin, erythromycin and
tetracycline, affect the ribosomes where protein formation
occurs, causing errors in the incorporation of amino acids.'
Mutations of various types can be envisaged which
would confer resistance to antibiotics. Any mutation which
altered the nature of the bacterial membrane in such a way
as to prevent the entrance of an antibiotic into the cell or
prevent its reaction with the membrane would confer
resistance. Other mutations cause the cellular production
of enzymes which are capable of inactivating antibiotics.
Mutations are also known which change the structure of
organelles in such a way that they are no longer sensitive
to the action of a particular antibiotic.
It must be emphasized that mutation in bacteria, as in
higher organisms, is a random, non-directed process.
Mutation to resistance to antibiotics has been shown to be
pre-adaptive and not postadaptive, as was widely believed
earlier.8 This means that a mutation to resistance may
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occur by chance at any time in any cell, irrespective of
whether 9r not that cell or any of its ancestors has ever
been in contact with the particular antibiotic. A mutation
to resistance may occur before exposure to the drug, and
does not arise as a result of an adaptation of metabolic
pathways occurring due to exposure. It has been shown
that some bacteria isolated before the use of a particular
antibiotic may carry genetic resistance to that antibiotic.
Once a mutation to antibiotic resistance has occurred in
a bacterial cell, it may be transferred to the progeny of
that cell during ordinary cell division, or to other cells by
a variety of different means by which some bacteria are
able to transfer genetic material. The inheritance of a
particular form of resistance depends on the number of
separate genes necessary to confer resistance and on the
type of gene involved (chromosomal or extrachromoso-
mal).
Monogenic and Polygenu: Resistance
It has been shown that resistance to high concentrations
of streptomycin or isonicotinic acid hydrazide (isoniazid)
may be acquired by bacteria by the mutation of a single
gene.s On the other hand, high-level resistance to penicillin
and most other antibiotics cannot be acquired in one muta-
tional step, but requires the simultaneous presence of
mutations in a number of different genes. If a large popu-
lation of sensitive cells is treated with a high concentra-
tion of streptomycin, we should expect that one in a
million of these cells (taking 10-· as an average mutation
rate) might have undergone a mutation to resistance during
one generation. Note that this figure is independent of
drug treatment, i.e. just as many mutations may be ex-
pected in the absence of the drug as in its presence. The
sensitive cells will be killed by the drug, but the few
resistant cells will soon multiply and form a new, highly-
resistant population. On the other hand, if resistance to
high concentrations of penicillin requires the presence in
any cell of, say, 5 different mutant genes, each of which
mutates at a rate of 10'·, then the chance of these 5
mutations occurring in the same cell during the same
generation is only 10-30•
Each individual gene causing resistance to penicillin
confers a slight degree of resistance, and these act addi-
tively. If a low concentration of penicillin is used on an
initially sensitive population, we should expect 5 x 10'·
cells to have undergone a single resistance mutation in any
generation. The penicillin will kill the completely sensitive
cells and a new population of low-level resistants will
establish itself. If the concentration of drug is now
doubled, 4 x 10-· of the low-level resistant cells (all of
which now carry one gene for resistance) will have under-
gone mutation of a second gene. By stepwise increase of
drug concentration with sufficient time for cell prolifera-
tion between increases, a population of high-level resist-
ants can be selected. The therapeutic implications of the
monogenic and polygenic forms of inheritance will be
discussed later.
Inheritance and Transfer of Resistance Genes
A. Chromosomal genes. Genes for resistance to anti-
biotics located on the bacterial chromosome may be trans-
ferred to other cells in the following way (see Hayes for
review) :'
1. By normal cell division. Each resistant cell, when
it divides, passes its resistance genes to each of its 2
daugh ter cells.
2. By conjugation. Episornic fertility factors exist in
some species of bacteria. These extrachromosomal pieces
of DNA may replicate independently of the chromosome
in the cytoplasm, or may become incorporated into the
chromosome and behave as if they were an integral part
of it. Alternation between the chromosomal and cytoplas-
mic states occurs. When present in cells, these fertility
factors such as K12, the well-studied F factor of E. coli,
alter the host cell in such a way that it is able to form a
conjugation tube with another cell lacking an F factor and
transfer either the F factor itself (when it is in the cyto-
plasmic state) or a part of the bacterial chromosome (when
F is in the chromosomal state). Recombination occurs be-
tween the DNA of the donor and recipient cells and any
gene of the donor may be incorporated into the chromo-
some of the recipient.
3. By transformation. Free DNA isolated from bac-
teria of some species can enter competent cells and re-
combine with the recipient cell's D A. In this way small
blocks of genes may be transferred.
4. By transduction. Some bacteriophages are capable of
including host bacterial DNA molecules in their protein
coats in the course of intracellular multiplication. When
these phages attack other bacteria, recombination for
small blocks of genes can occur between the DNA ob-
tained from the previous host and that of the present host.
Since a transducing phage has usually substituted bacterial
DNA for a part of its own viral DNA, the remaining
viral genome is unable to complete the course of infection,
and the infected cell survives. Resistance genes, like any
other bacterial genes, may be transmitted from one cell to
another by transducing phages.
Transformation and transduction studies provide a con-
venient method for studying the mode of inheritance of
resistance to a particular antibiotic. Since only a small
piece of the DNA of the donor cell is transferred at a
time to the recipient cell, resistance due to a single gene
may be transferred in one step of transformation or trans-
duction, while a resistance based on polygenes cannot be
transformed or transduced in one step.
B. Resistance controlled by genes carried by plasmids
and episomes. In addition to their normal complement of
genes carried on the chromosome, bacteria may also carry
extra genetic material in cytoplasmic plasmids or episomes,
such as the F factor mentioned above. These classes of
genetic elements which are not necessary for the normal
existence of bacteria have only recently been discovered
to be of great importance in the problem of drug resist-
ance. Watanabe and Fukasawa in Japan first isolated
shigella strains that were resistant to high concentrations
of several antibiotics.'" It was subsequently shown that
this resistance was not of the usual chromosomal type but
was carried by cytoplasmic resistance factors. These R
factors are D A, and usually carry genes which act as
fertility factors, allowing the cells which contain them to
conjugate with other cells lacking them. They also carry
genes which permit their independent replication, gene
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for resistance for various numbers of antibiotics and
sometimes genes which confer an abnormally high re-
sistance to certain metal ions." Judging from their size,
they probably also carry additional genes whose functions
are as yet unknown. The R factors are readily passed
from one cell to another of the same species, or, in some
cases, to different species during conjugation. In this way
resistance to a number of antibiotics can be transferred
simultaneously from harmless enteric bacteria to patho-
genic species.
The origin of R factors is not known and the resistance
genes they carry appear to be different from the known
chromosomal genes conferring resistance to the same
antibiotics. Resistance to each of the antibiotics carried
by the R factors seems to be of a single gene type rather
than the polygenic type carried by the chromosomes.
Different R factors may also carry different genes for
resistance to the same antibiotic." The similarity of R
factors to episomes such as F and to prophages, together
with the established fact that some episomes and phages
can exchange genes with the chromosome, makes it seem
likely that R factors are F factors which have at some time
in the past picked up resistance genes from the chromo-
some of some unknown organism."
Possible Host Factors
The aforegoing has placed prime emphasis on bacterial
genetics in the development of microorganismal resistance
to antibiotics during therapy. Very little is known about
possible host factors in this regard. One may consider
poor absorption of antibiotics in sick patients, walled-off
lesions, inadequate protein binding and transfer of the
drug to the site of infection, development of antibodies to
the antibiotic being used and changes in local tissue pH
during infection. The only well-documented host factor
important in altering the sensitivity of urinary bacteria to
antibiotics is the pH level of the urine. Thus benzyl-
penicillin, ampicillin, oxytetracycline and sulphathiazole
have an increased antibacterial effect in acid conditions
and vice versa. On the other hand, streptomycin and
kanamycin are most active in alkaline media and kana-
mycin is almost without effect in acid conditions."
THE CHANGING SPECTRUM OF BACTERIAL RESISTANCE
With the genetic mutational model in mind, it is propitious
to pass to a consideration of the changed spectrum of
bacterial resistance to antibiotics over the last few decades.
The recognition of the development of bacterial resistance
to an antibiotic may be made on clinical and bacteriologi-
cal grounds. Clinically, there will be initial improvement
in the patient's condition, and then, as the mutant re-
sistant strain emerges and proliferates, so will there be a
recrudescence of the patient's symptoms and signs. From
the bacteriological viewpoint, a fall-and-rise phenomenon
will be observed. For example, in the case of tuberculosis
treated with isoniazid or streptomycin alone, the viable
population of a culture or a lesion exposed to the drug
initially shows a fall associated with killing of the sensi-
tive organisms, followed by a rise as the resistant mutants
multiply and replace them." Further, resistant organisms
can be isolated in culture and then tested for resistance to
varying concentrations of the antibiotic concerned. The
serologic and other characteristics of the resistant mutant
may also be established.
A study cannot be made of all the organisms pathogenic
to man. One method of approach is to consider serially
the more common microorganisms and their sensitivity
or resistance to various antibiotics."
Staphylococci
. The mutation potential of these COCCI IS high." The
emergence and dissemination, especially within the hospi-
tal milieu, of resistant staphylococci have caused serious
concern in recent years. Penicillinase-producing staphylo-
cocci have exhibited resistance to penicillin G, tetracy-
elines, streptomycin, cWoramphenicol, erythromycin, novo-
biocin and neomycin as each drug came into use. At
present nearly two-thirds of staphylococci isolated from
patients are resistant to penicillin G, streptomycin, tetra-
cycline or erythromycin, and a smaller proportion are
resistant to chloramphenicol and novobiocin.1B Practically
all strains are still sensitive to vancomycin and bacitra-
cin.m,'" The introduction of methicillin in 1959 seemed to
be an answer to this problem. However, methicillin-resist-
ant strains of Staph. aureus (coagulase positive) were first
recognized in England in 1960." Such strains have subse-
quently been recognized elsewhere. They are pathogenic
in man and infection may have fatal consequences." These
methicillin-resistant strains of Staph. aureus have rather
consistent characteristics. They are all resistant to peni-
cillin, streptomycin, tetracycline, oxacillin, cloxacillin,
nafcillin and certain of the cephalosporins, and many are
also resistant to cWoramphenicol and erythromycin.%3
These strains existed before the introduction of methicillin
and have spread alarmingly in hospitals in the last few
years,%3 although there is little evidence that such spread is
directly related to the use of methicillin in hospitals." The
fact that methicillin-resistant strains are also resistant to
many other antibiotics, as outlined above, probably ex-
plains their selection and spread in hospitals." Despite the
fact that their incidence is low at present, these strains are
widespread, virulent and communicable, and it is likely that
they will continue to survive and spread.
Group A Streptococci
Penicillin remains the drug of choice in the prophylaxis
and therapy of group A streptococcal infections. There is
no evidence of naturally-occurring penicillin-resistant
strains. Clinically, group A streptococci may fail to be
eliminated from an infected area by the concomitant
presence of penicillinase-producing Staph. aureus. The
latter destroys the penicillin and therefore the streptococci
survive."" Penicillin-resistant streptococci have, however,
been successfully selected for in vitro studies.""
Sulphonamides. A programme of mass sulphadiazine
prophylaxis carried out in the armed forces during World
War II produced an initial dramatic effect, but later the
emergence of sulphonamide-resistant strains occurred.
These strains have not led to any serious problem in
civilian life."
Erythromycin. This is the best antibiotic for strepto-
coccal eradication in patients allergic to penicillin. Only
one instance of naturally-occurring resistant strains has
been reported, and this in a centre where erythromycin
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was extensively used in the control of infection,"
Tetracyclines. Group A streptococci, resistant to tetra-
cyclines, were first isolated from man in 1952.28 Since this
original observation, resistant strains have been found in
various areas. These strains are resistant to tetracycline,
cWortetracycline, oxytetracycline and dimethylchlortetra-
cycline. The resistant strains are as virulent as the sensi-
tive ones and tetracyclines should not be used as effective
substitutes for penicillin or sulphonamides for strepto-
coccal prophylaxis. Moreover, these drugs are unsatisfac-
tory therapeutic agents for established streptococcal infec-
tion, and even if the organism is sensitive, they are inferior
to penicillin or erythromycin.
Pneumococci
Penicillin remains the antibiotic of choice for the treat-
ment of pneumococcal infections. Despite extensive and
long usage there are no reports of penicillin-resistant
pneumococci and there is no trend towards decreasing
susceptibility."
Erythromycin likewise remains efficacious in pneumo-
coccal infections" and is the best alternative agent for
pneumococcal therapy in patients who cannot be given
penicillin.
Tetracycline-resistant pneumococci were reported in
Australia in 196230 and subsequently in other countries.
With this resistance, there is a marked correlation with
previous tetracycline therapy. The hospital may be an
important site for the transmission of resistant strains and
the term 'hospital pneumococcus' has been coined." Tetra-
cycline-resistant strains appear late and the reasons for
this are unknown. '
M eningococct .
Until 1963 the sulphonamides were regarded as the
agents of choice for both the prophylaxis and therapy of
meningococcal infections. At that time an outbreak of
meningococcal disease occurred at 2 naval installations in
California. Adequate proof was obtained for the existence
of sulphonamide-resistant meningococci-both in prophy-
laxis and therapy." Later evidence was forthcoming that
sulphonamide-resistant meningococci are distributed
throughout the civilian population of the USA. It is of
interest to note that most of the recent cases of meningo-
coccal infection were due to groups Band C, while group
A was the main offender during World War n." Almost
all the sulphonamide-resistant meningococci have been of
group B, with a few resistant strains from group C. It is
now clear that sulphonamides can no longer be relied
upon for chemoprophylaxis or therapy of meningococcal
infections. Penicillin G, however, is the therapy of choice
and is most efficacious in the management of meningo-
coccal meningitis or infections where sulphonamide-
resistant strains exist. Chloramphenicol is a valuable sub-
stitute in patients allergic to penicillin.
Gonococci
Sulphonamides were initially used with high success-
rates in gonococcal infections'" While almost all strains
of gonococci were initially susceptible, with cure rates of
up to 90%, resistant forms soon emerged and shortly be-
fore World War II therape.utic failures of near 85% were
experienced. At this time penicillin was introduced and
was highly active against all strains and effective treat-
ment was once more obtained. However, strains of gono-
cocci with decreased sensitivity to penicillin then made
their appearance." Whereas previously, cure in 90 - 100%
of cases of gonorrhoea was obtained with a single injection
of 300,000 units of penicillin, the practice now, in the
Light of decreased sensitivity, is to use a minimal dosage
of" nearly 2·5 million units of penicillin G.
Tetracyclines are also of value and no resistance has
been found. Rapid emergence of resistance followed use
of streptomycin. Erythromycin and chloramphenicol pro-
vide alternate modes of attack.
The Enterobacteriaceae
While the enterobacteriaceae have generally been con-
sidered as relatively harmless constituents of the normal
bowel flora, the bacterial disease spectrum has shown
remarkable changes inasmuch as many of these bacteria
are now causative of serious infections and pathology in
man. They mutate readily. In a hospital population under
study, enteric organisms such as Escherichia coli, proteus
species, A. aerogenes, Ps. aeruginosa and enteric cocci
accounted for only 12% of the infections and 9% of the
deaths in 1935 ; but in 1957 they accounted for more than
one-third of bacterial infections and about half of the
deaths from bacteraemia."
The increased prevalence of serious infections caused
by enteric bacteria is due to:
(a) certain strains of enterobacteriaceae naturally re-
sistant to antimicrobials increasing in number as
other sensitive strains are eliminated,
(b) resistant mutants from originally sensitive strains
emerging under the selective influence of antibiotics,
and
(c) resistance factors, as described above, which may
confer resistance on other enterobacteriaceae or on
other Gram-negative organisms.
The proportion of antibiotic-resistant enteric bacteria
isolated from infected patients has increased since the
introduction of antibiotics." Enteropathogenic E. coli re-
sistant to neomycin, kanamycin, tetracycline or chloram-
phenicol are documented. R factors mediate resistance to
sulphonamides, chloramphenicol, streptomycin and tetra-
cycline," and also to neomycin and kanamycin," ampicillin
and cephalothin," and furazolidine."" More recently, re-
sistance of the same type to several new aminoglycosides
such as bluensomycin, spectinomycin and gentamicin has
been reported.'
While most strains of E. coli isolated from clinical
sources remain sensitive to ampicillin, colistimethate, tetra-
cycline or chloramphenicol, the 'hospital strains' are much
more resistant to tetracycline or chloramphenicoL'·
Shigellae resistant to suI phonamides, streptomycin,
chloramphenicol and tetracyclines have been described.
Although Salmone!la typhosa can receive multiple resist-
ance factors in vitro from organisms with such R factors,
wild strains of S. typhosa possessing R factors have not
yet been isolated." In India, about 9% of 687 S. typhosa
strains were resistant to at least 16 p.g./ml. of chloram-
phenicol." However, the incidence in South Africa of
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strains resistant to more than 10 fLg./ml. of chlorampheni-
col is only 0·8%." The absence of R factors among wild
strains of S. typhosa is difficult to explain.
THERAPEUTIC MEASURES
From the aforegoing discussion on the changing spectrum
of drug resistance and its explanation in terms of bacterial
genetics, a few therapeutic pointers arise:
The correct antibiotic for the particular organism should
be selected whenever possible. This obviates overgrowth
of the organism (at the expense of other flora), where it is
entirely non-sensitive, and where it is partly sensitive, the
eventual emergence by serial mutation of full-blown
resistance is avoided.
The drug should be administered for a sufficient length
of time. By lengthy dosage, the phenomenon of microbial
persistence is avoided. Several microbes may not divide
for short periods during exposure to antibiotics and may
thus survive brief dosage schedules.
The drug should be given in adequate dosage. Small
doses are likely to lead to the emergence of drug resist-
ance because sensitive or partially sensitive microbes are
'given the chance or time' to mutate further and resistance
is consequently selected.
Antibiotics should, in certain cases, be used in combina-
tion. This is particularly true for therapy of tuberculosis
where a one-step mutational resistance to streptomycin is
common and is prevented by use of streptomycin in
combination with INH or PAS.
There seems to be little which can be achieved in the
case of resistance determinants and their transfer factors.
R-factor-mediated resistance in all enterobacteriaceae and
several other genera of Gram-negative bacteria remains
one of the most serious challenges and dangers of the
present antibiotic era. In vitro studies show that bacteria
can be 'cured' of R factors as well as other cytoplasmic
episomes by treatment with acridine dyes." Therefore,
deeper understanding of this phenomenon at the intra-
cellular level will hopefully lead to a solution in vivo.
SUMMARY
The development of bacterial resistance to antibiotics during
therapy poses challenging biological and clinical problems.
Over the last few decades the susceptibility of various micro-
organisms to antibiotics has changed. The changed pattern is
outlined. A major factor in its development has been the
widespread misuse of antibiotics. Their extensive and often
indiscriminate use in man and animals has served as a form
of natural selection for the emergence of resistant mutants.
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